Theodore Cohen
Long only, biotech, healthcare, mid-cap

Vical's Allovectin Phase III Trial Results: Consider The Possibilities

On June 29-30, 2013, I interviewed Suleman Verjee, PhD, President and CEO of Versante International. Based in Oakland, CA, Versante is a leader in leveraging biometrics, Statistical Analysis Software (SAS) programming, and data management to provide strategic leadership for drug development plans, protocol development and regulatory submissions. Dr. Verjee, the founder of Versante, is a statistician with more than 30 years of pharmaceutical industry experience focused on assisting companies with new drug application (NDA) and biologics license application (BLA) submissions, streamlining data operations and optimizing clinical development plans. He has been associated with the development, submission and/or approval of several blockbuster drugs and retains a 100% success rate with every drug submission in which he has been actively involved....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details